Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 3045-3052

  Okuno, Kiyotaka ^a   Sugiura, Fumiaki ^a   Inoue, Keisuke ^a   Sukegawa, Yasushi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

7 peptide vaccine; Cancer vaccine; Clinical trial; Metastatic colorectal cancer; Oral chemotherapy; Refractory to standard chemotherapy

Indexed keywords

BILIRUBIN; CANCER VACCINE; FOLINATE CALCIUM; FORKHEAD BOX M1; HLA A24 ANTIGEN; HOLLIDAY JUNCTION RECOGNIZING PROTEIN; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; PEPTIDE VACCINE; RING FINGER PROTEIN 43; TRANSLOCASE OF THE OUTER MITOCHONDRIAL MEMBRANE 34; TUMOR ANTIGEN; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; SUBUNIT VACCINE; TUMOR MARKER;

ADULT; AGED; ANAPHYLAXIS; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CANCER SURVIVOR; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; COUGHING; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNE RESPONSE; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE REDNESS; LONG TERM SURVIVAL; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; REST; SEIZURE; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; 7-PEPTIDE VACCINE; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; FOLLOW UP; IMMUNOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; ORAL CHEMOTHERAPY; ORAL DRUG ADMINISTRATION; PROGNOSIS; REFRACTORY TO STANDARD CHEMOTHERAPY; SURVIVAL RATE;

7-PEPTIDE VACCINE; CANCER VACCINE; CLINICAL TRIAL; METASTATIC COLORECTAL CANCER; ORAL CHEMOTHERAPY; REFRACTORY TO STANDARD CHEMOTHERAPY;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VACCINES, SUBUNIT;

EID: 84906315989     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC and Nakamura Y: Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128, 2002.
2. Okuno K, Sugiura F, Hida J, Tokoro T, Ishimaru E, Sukegawa Y, Ueda K: Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med 2: 73-79, 2011.
3. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP and Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8: 1369-1375, 2002.
4. Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T an Nakamura Y: A novel oncoprotein RNF43 functions in autocrin manner in colorectal cancer. Int J Oncol 25: 1343-1348, 2004.
5. Shimokawa T, Matsushima S, Tsunoda T, Nakamura Y an Furukawa Y: Identification of TOMM34, which shows elevate expression in the majority of human colon cancers, as a nove target. Int J Oncol 29: 381-386, 2006.
6. Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikut Y, Harao M, Imai K, Baba H, Iwase H, Nomori H, Takahashi K Daigo Y, Tsunoda T, Nakamura Y, Sasaki Y and Nishimura Y The forkhead box M1 transcription factor as a candidate of targe for anticancer immunotherapy. Int J Cancer 126: 2153-2163 2010.
7. Lin ML, Park JH, Nishidate T, Nakamura Y and Katagiri T Involovement of maternal embryonic leucine zipper kinas (MELK) in mammary carcinogenesis through interaction wit BCL-G, a proapoptotic member of the BCL-2 family. Breas Cancer Res 9: R17, 2007.
8. Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M Kondo S, Nakamura Y and Daigo Y: Activation of Hollida junction recognizing protein involved in the chromosomal stabilit and immortality of cancer cells. Cancer Res 67: 8544-8553, 2007
9. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M an Tahara H: Inhibition of tumor growth with antiangiogenic cance vaccine using epitope peptides derived from human vascula endothelial growth factor receptor 1. Clin Cancer Res 12: 5841 5849, 2006.
10. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M and Tahara H: Rational for antiangiogenic cancer therapy wit vaccination using epitope peptides derived from human vascula endothelial growth factor receptor 2. Cancer Res 65: 4939-4946 2006.
11. Common Terminology Criteria for Adverse Events v.4. (CTCAE v.4.0) (http://evs.nci.nih.gov/ftp1/CTCAE-4.03-2010 06-14-QuickReference-8.5X11.pdf), 2010
12. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N Harper P, Vincent MD, Lembersky BC, Thompson S, Manier A and Benner SE: Multicenter phase III study of uracil/tegafu and oral leucovorin versus fluorouracil and leucovorin in patient with previously untreated metastatic colorectal cancer. J Cli Oncol 20: 3605-3616, 2002.
13. Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki and Okuno K: Immunological evaluation of personalized peptid vaccination in combination with UFT and UZEL for metastati colorectal cancer patients. Cancer Immunol Immunother 58 1845-1854, 2009.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT Christian MC and Gwyther SG: New guidelines to evaluate th response to treatment in solid tumors. European Organization fo Research and Treatment of Cancer, National Cancer Institute o the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92: 205-216, 2000.
15. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K Tsunoda T and Nakamura Y: Multicenter, phase II clinical tria of cancer vaccination for advanced esophageal cancer with thre peptides derived from novel cancer-testis antigens. J Transl Me 10: 141, 2012.
16. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM and Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57: 303-315, 2008.
17. FDA Guidance for Industry Clinical Considerations for Therapeutic Cancer Vaccines (http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf), 2011.
18. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanka A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trauwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak J, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C and Singh-Jasuja H: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18: 1254-1261, 2012.
19. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 12: 252-263, 2012.
20. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tobernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, for the CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase III trial. Lancet 381: 303-312, 2013.